Featuring a slide presentation and related discussion from Prof Peter Schmid, including the following topics:

• Evolution of the therapeutic landscape for metastatic triple-negative breast cancer; age of immunotherapy (0:00)
• Case: A woman in her early 40s with no actionable mutations (7:29)
• Evolution of antibody-drug conjugates (ADCs) in the management of metastatic breast cancer (11:13)
• TROP2-directed ADCs (15:22)
• Case: A woman in her early 50s with PD-L1-negative, HR-negative, HER2-low de novo metastatic breast cancer (20:21)
• Novel strategies utilizing approved and investigational ADCs (23:28)
• Case: A woman in her early 60s with loss of HER2 expression on disease progression (31:39)
• ADCs in combination with immunotherapy (32:51)

CME information and select publications

Featuring an interview with Dr Jonathan Strosberg, including the following topics:

• Overview of extrapulmonary neuroendocrine carcinoma (NEC) (0:00)
• Treatment strategies for extrapulmonary NEC (10:26)
• Targeting DLL3 in extrapulmonary NEC (18:49)
• Early clinical data with obrixtamig for extrapulmonary NEC (21:56)
• Additional investigational agents for extrapulmonary NEC (25:44)
• Case: A woman in her mid 50s with poorly differentiated metastatic NEC of unknown primary (27:20)
• Case: A man in his early 60s with poorly differentiated metastatic esophageal NEC (32:30)
• Clinical management of well-differentiated NEC (36:58)

CME information and select publications

Featuring an interview with Dr Beth Faiman, including the following topics:

• Clinical practice background and historical view of treatment for multiple myeloma (MM) (0:00)
• Fundamental principles associated with chimeric antigen receptor (CAR) T-cell therapy (7:19)
• Sequencing of CAR T-cell therapy and bispecific antibodies in the MM treatment landscape (9:00)
• Patient eligibility to receive CAR T-cell therapy (13:23)
• Differentiating among approved CAR T-cell therapies for MM (18:18)
• Durability of responses to CAR T-cell therapy for MM (24:01)
• Neurotoxicity with CAR T-cell therapies for MM (26:26)
• Minimal residual disease monitoring in MM (29:39)
• Support systems for the management of toxicities associated with CAR T-cell therapy (35:10)
• Patients with MM experiencing durable responses to CAR T-cell therapy (43:11)

NCPD information and select publications

Featuring a slide presentation and related discussion from Dr Jonathan Strosberg, including the following topics:

• Overview of the classification, grading and incidence of neuroendocrine carcinoma (NEC) (0:00)
• Overview of mutational profile, biomarker assessments and prognosis of NEC (3:45)
• Current treatment paradigm for extrapulmonary NEC (8:59)
• DLL3 as an emerging target biomarker in extrapulmonary NEC (17:46)
• Novel therapeutic agents under investigation for extrapulmonary NEC (23:05)

CME information and select publications

Featuring perspectives from Dr Ana C Garrido-Castro and Prof Peter Schmid, including the following topics:

• Introduction: Legendary Figures in Breast Cancer Research (0:00)
• Case: A woman in her early 80s, a current smoker with a history of myocardial infarction and stroke, who develops recurrent triple-negative breast cancer (TNBC) — Justin Favaro, MD, PhD (6:44)
• Case: A woman in her late 60s with metastatic TNBC and a PD-L1 level of 20% who receives chemotherapy/pembrolizumab followed by sacituzumab govitecan — Priya Rudolph, MD, PhD (25:08)
• Case: A woman in her late 60s with localized TNBC who develops myocarditis while receiving neoadjuvant chemotherapy/pembrolizumab — Richard Zelkowitz, MD (33:53)
• Case: A woman in her mid 60s with recurrent ER-negative, HER2-low, PI3K-mutant TNBC — Ranju Gupta, MD (37:49)
• Case: A woman in her early 60s with recurrent TNBC confined to contralateral neck nodes — Eric H Lee, MD, PhD (42:10)
• Case: A woman in her early 40s with metastatic TNBC who receives sacituzumab govitecan after multiple lines of chemotherapy — Estelamari Rodriguez, MD, MPH (48:10)
• Case: A woman in her mid 70s with ER-negative, HER2-low breast cancer who develops an isolated brain metastasis — Dr Gupta (55:02)

CME information and select publications

Featuring an interview with Dr Neel Pasricha, including the following topics:

• Anatomy and physiology of the cornea; intersection of ophthalmology and oncology for patients receiving antibody-drug conjugates (ADCs) (0:00)
• Association of corneal toxicities with ADCs (4:56)
• Dose and schedule modifications to mitigate ocular toxicities associated with belantamab mafodotin and other ADCs (9:02)
• Spectrum and severity of corneal toxicities associated with datopotamab deruxtecan (14:44)
• Role of optometrists and ophthalmologists in screening for and management of ocular toxicities (17:55)
• Other ocular toxicities associated with cancer therapies (24:26)
• Prevention and management of corneal toxicity (33:58)
• Preexisting ophthalmic conditions as potential risk factors for development of ocular toxicities with ADCs (43:39)
• General clinical pearls on the management of ocular toxicities with cancer therapies (48:04)

CME information and select publications

Featuring perspectives from Prof Rebecca A Dent, Dr Hans Lee, Dr Neel Pasricha and Dr Tiffany A Richards, including the following topics:

• Introduction: The Patient Experience (0:00)
• Managing Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies — Dr Pasricha (10:28)
• Ocular Toxicities in Multiple Myeloma (45:33)
• Ocular Toxicities in Breast Cancer (50:34)

CME information and select publications

Featuring an interview with Dr Jacob Sands, including the following topics:

• Management of Adverse Events of Special Interest Associated with Datopotamab Deruxtecan (Dato-DXd) (0:00)
  • Heist RS et al. Clinical management, monitoring, and prophylaxis of adverse events of special interest associated with datopotamab deruxtecan. Cancer Treat Rev 2024;125:102720. Abstract
  • Sands J et al. Analysis of drug-related interstitial lung disease (ILD) in patients (pts) treated with datopotamab deruxtecan (Dato-DXd). ASCO 2024;Abstract 8623.
• Intracranial Efficacy of Dato-DXd for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Actionable Genomic Alterations in the TROPION-Lung05 Study (7:23)
  • Lisberg A et al. Intracranial efficacy of datopotamab deruxtecan (Dato-DXd) in patients (pts) with previously treated advanced/metastatic non-small cell lung cancer (a/m NSCLC) with actionable genomic alterations (AGA): Results from TROPION-Lung05. ASCO 2024;Abstract 8593.
• Clinical Evidence Supporting the Combination of Dato-DXd with Immune Checkpoint Inhibition for Advanced NSCLC (12:12)
  • Bessede A et al. TROP2 is associated with primary resistance to immune checkpoint inhibition in patients with advanced non-small cell lung cancer. Clin Cancer Res 2024;30(4):779-85. Abstract
  • Levy BP et al. TROPION-Lung02: Datopotamab deruxtecan (Dato-DXd) plus pembrolizumab (pembro) with or without platinum chemotherapy (Pt-CT) as first-line (1L) therapy for advanced non-small cell lung cancer (aNSCLC). ASCO 2025;Abstract 8501.
  • Waqar SN et al. First-line (1L) datopotamab deruxtecan (Dato-DXd) + rilvegostomig in advanced or metastatic non-small cell lung cancer (a/mNSCLC): Results from TROPION-Lung04 (cohort 5). ASCO 2025;Abstract 8521.
• Current and Future Development of Antibody-Drug Conjugates in the Treatment of Lung Cancer (17:11)
  • Tawfiq RK et al. Targeting lung cancer with precision: The ADC therapeutic revolution. Curr Oncol Rep 2025;27(6):669-86. Abstract

CME information and select publications